Symptoms of delayed gastric emptying, nausea and vomiting are listed as side effects
Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease
The right weight management program is one that aligns with your health profile, your financial situation, and your expectations - with full transparency about regulatory status, program terms, and what the evidence actually shows
Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimers disease
Do not administer the preserved formulation to patients with known hypersensitivities to preservatives.
